Compare LBRT & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LBRT | CELC |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.3B |
| IPO Year | 2017 | 2017 |
| Metric | LBRT | CELC |
|---|---|---|
| Price | $19.83 | $89.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 9 |
| Target Price | $27.50 | ★ $112.56 |
| AVG Volume (30 Days) | ★ 3.7M | 1.6M |
| Earning Date | 04-22-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $4,006,116,000.00 | N/A |
| Revenue This Year | $0.27 | N/A |
| Revenue Next Year | $7.44 | $720.19 |
| P/E Ratio | $140.14 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.90 | $34.30 |
| 52 Week High | $34.48 | $151.02 |
| Indicator | LBRT | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 42.86 | 39.88 |
| Support Level | $22.89 | $83.77 |
| Resistance Level | $26.77 | $117.54 |
| Average True Range (ATR) | 1.09 | 6.54 |
| MACD | 0.23 | -1.39 |
| Stochastic Oscillator | 48.32 | 12.43 |
Liberty Energy Inc is a integrated energy services and technology company focused on providing hydraulic fracturing services and related technologies to onshore oil and natural gas exploration and production (E&P) companies. The Company offers customers with hydraulic fracturing services, together with complementary services including wireline services, proppant delivery solutions, field gas processing and treating, compressed natural gas (CNG) delivery, data analytics, related goods (including sand mine operations), and technologies to facilitate lower emission completions, thereby helping customers reduce emissions profile. The company provides services across USA and Canada.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.